research Local Therapy of Androgenetic Alopecia with 17 Alpha-Estradiol: A Controlled, Randomized Double-Blind Study
Hair lotions with 17 alpha-estradiol can reduce hair loss but won't regrow new hair.
Search
for
Sort by
Research
30 / 1000+ results 
research The Efficacy and Safety of 17α-Estradiol (Ell-Cranell Alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study
17α-Estradiol solution safely improves hair density and thickness in female pattern hair loss.
research Development Of Lipid-Based Nanostructured Formulation Using Myristyl Myristate For Carrying Estradiol
A new lipid-based formula using myristyl myristate can improve estradiol treatment for hair loss.
research Review of the Effects of 17α-Estradiol in Humans: A Less Feminizing Estrogen with Neuroprotective Potential
17α-estradiol is a safe estrogen that might protect the brain and doesn't cause feminization, needing more research for treating brain diseases.
research An Estrogen Receptor Pathway Regulates the Telogen-Anagen Hair Follicle Transition and Influences Epidermal Cell Proliferation
Estrogen affects hair growth and skin cell multiplication.
research Acute Localized Exanthematous Pustulosis Caused by Topical Application of Minoxidil
Minoxidil can cause a skin reaction called ALEP.
research Therapeutic Efficacy of a Combination Therapy of Topical 17α-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation
Combination of 17α-estradiol and minoxidil improves hair growth and reduces hair loss in most patients.
research Estrogens And The Hair Follicle
Estrogens generally inhibit hair growth and improve skin quality, but their exact effects on hair follicles are complex and not fully understood.
research Estrogens and Human Scalp Hair Growth: More Questions Than Answers
The effects of estrogen on human hair growth are unclear and need more research.
research Androgenetic Alopecia: An Update
Minoxidil and finasteride effectively treat hair loss.
research Current and Future Medical Treatment of Androgenetic Alopecia
Treatments for hair loss vary, but cell-based options may be the future.
research 5α-Reductase Isozymes and Androgen Actions in the Prostate
5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.
research The Pathogenesis and Treatment Progress of Androgenic Alopecia
Future treatments for androgenic alopecia may focus on reactivating hair follicle stem cells and improving drug delivery.
research Understanding Patient and Physician Perceptions of Male Androgenetic Alopecia Treatments in Asia-Pacific and Latin America
Patients and doctors find current hair loss treatments unsatisfying and believe involving patients in decisions improves results.
research Androgenetic Alopecia: Therapy Update
There are many treatments for common hair loss, but more trials are needed to decide which are best.
research Biology of Estrogens in Skin: Implications for Skin Aging
Estrogens can improve skin aging but carry risks; more research is needed on safer treatments.
research Physiopathology and Current Treatments of Androgenetic Alopecia: Going Beyond Androgens and Anti-Androgens
Hair loss treatments work better with lifestyle changes.
research Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures
A blood pressure drug, diltiazem, may also help treat influenza.
research Hormonal Changes in Menopause: Do They Contribute to a Midlife Hair Crisis in Women?
Menopause-related hormonal changes affect hair but are not the only cause of hair changes in middle-aged women.
research Interventions for Female Pattern Hair Loss
Minoxidil effectively treats female pattern hair loss.
research Guidelines for Management of Androgenetic Alopecia Based on BASP Classification: The Asian Consensus Committee Guideline
Use 5% minoxidil or oral finasteride for mild-to-moderate hair loss, combine with hair transplant for severe cases.
research Androgens Modulate Keratinocyte Differentiation Indirectly Through Enhancing Growth Factor Production From Dermal Fibroblasts
Male hormones indirectly affect skin cell development by increasing growth factor levels from skin fibroblasts.
research Alfatradiol (0.025%) - An Effective and Safe Treatment Option for Androgenetic Alopecia in Women and Men
Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
research Telogen Effluvium: Comprehensive Overview and Treatment
Telogen Effluvium is a hair loss condition where treatment involves identifying and managing its triggers.
research Potential Efficiency of Antioxidants to Prevent Pressure Ulcers: A Neglected Hypothesis
Antioxidants might help prevent pressure ulcers, but more research is needed to find effective ones.
research Androgenic Alopecia: Pathogenetic Mechanisms and Therapeutic Approaches
The document concludes that current treatments for androgenic alopecia are not fully effective, but new therapies like botulinum toxin and PRP show promise, and future gene therapy could be beneficial.
research Immuno-Endocrinology of COVID-19: The Key Role of Sex Hormones
Sex hormones may affect COVID-19 severity, with estrogen possibly reducing risk and testosterone potentially increasing it.
research Development and Skin Penetration Pathway Evaluation Using Confocal Laser Scanning Microscopy of Microemulsions for Dermal Delivery Enhancement of Finasteride
Finasteride-loaded microemulsions can effectively enhance skin delivery for treating hair loss.
research Guidelines Based Management of Androgenetic Alopecia
The document concludes that personalized treatment plans for hair loss in Asian men are necessary and more research is needed to develop effective guidelines.
research Androgenetic Alopecia: Pathogenetic Mechanisms and Treatment Approaches
Androgenic alopecia, a common hair loss condition, is linked to changes in androgen metabolism and genetics, and can be treated with finasteride and minoxidil, but these treatments are only fully effective in 10% of patients.